No Data
Exchange-Traded Funds, Equity Futures Edge Higher Pre-Bell Tuesday Ahead of Consumer Confidence Data, US Treasury Buyback Announcement
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
Catalyst Pharma's FIRDAPSE Approved in Japan for Rare Autoimmune Disorder Lambert-Eaton Myasthenic Syndrome ("LEMS")
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE in Japan
High Growth Tech Stocks In The United States You Should Know
Despite the Downward Trend in Earnings at Catalyst Pharmaceuticals (NASDAQ:CPRX) the Stock Grows 4.2%, Bringing Three-year Gains to 288%
loading...